The Nikkei newspaper reported that we are preparing a clinical study using anti-periostin antibodies for chemotherapy-resistant triple-negative breast cancer.
Nikkei Electronic Edition

Triple-negative breast cancer is an intractable cancer that does not have HER2 in addition to estrogen and progesterone receptors, making targeted drugs ineffective. It is a disease with high unmet medical needs that occurs frequently in young women under the age of 40. In particular, chemotherapy-resistant triple-negative breast cancer has been reported to have an extremely poor prognosis. We have
developed an anti-periostin antibody as a treatment to suppress the emergence of breast cancer stem cells caused by epithelial-mesenchymal transition, which is the cause of
this. We plan to start clinical trials targeting recurrent and triple-negative breast cancer in Osaka and Tokyo in 2023. We are also considering applying this antibody to various intractable diseases in the future.